eli lilly glp 1 The U.S. Food and Drug Administration has approved Lilly's new weight-loss GLP-1 pill, orforglipron, which will be sold as Foundayo. 🔽🔗 Prime Labs GLP-1 Analogues Transform Metabolic Size:15 (on the go packets)

eli lilly glp 1 The U.S. Food and Drug Administration has approved Lilly's new weight-loss GLP-1 pill, orforglipron, which will be sold as Foundayo. 🔽🔗 Prime Labs GLP-1 Analogues Transform Metabolic Size:15 (on the go packets)

GLP-1 Analogues Transform Metabolic Disease Management | Universal Healthcare posted on the topic | LinkedIn

The criteria are: Automatic approval pathway (BMI 30 or higher): Current BMI of 30 kg/m² or higher Documentation of trial and failure of non-pharmacologic intervention No contraindications to the medication Conditional approval pathway (BMI 27 to 29.9): Current BMI of 27 to 29.9 kg/m² At least one documented weight-related comorbidity Documentation of trial and failure of non-pharmacologic intervention No contraindications to the medication Weight-related comorbidities CDPHP accepts: Type 2 diabetes (HbA1c 5.7% or higher, or prior diagnosis) Hypertension (documented BP 130/80 or higher, or on antihypertensive medication) Dyslipidemia (LDL 130 mg/dL or higher, triglycerides 150 mg/dL or higher, or on lipid-lowering medication) Obstructive sleep apnea (documented by sleep study) Non-alcoholic fatty liver disease (documented by imaging or biopsy) Osteoarthritis of weight-bearing joints (documented by imaging) Polycystic ovary syndrome (documented diagnosis) Cardiovascular disease (prior MI, stroke, or documented coronary artery disease) The comorbidity must be documented in the medical record with objective data (lab values, imaging reports, sleep study results)

Prime Labs

Size:15 (on the go packets)

A Western diet with alcohol in drinking water recapitulates features of alcohol-associated liver disease in mice